

An Overview of Funding Opportunities in the Division of Cancer Prevention

Vignesh Gunasekharan, PhD

On behalf of the Division of Cancer Prevention

MISSION STATEMENT

*The Division of Cancer Prevention furthers the mission of the National Cancer Institute by leading, supporting, and promoting rigorous, innovative research and training to prevent cancer and its consequences to improve the health of **ALL** people.*

Research Groups and Major Programs in DCP

11
Research
Groups



25 Programs

- Biometry
- Breast and Gynecologic Cancer
- Cancer Biomarkers
- Chemopreventive Agent Development – I and II
- Community Oncology and Prevention Trials
- Early Detection
- Gastrointestinal and Other Cancers
- Lung and Upper Aerodigestive Cancer
- Nutritional Science
- Prostate and Urologic Cancer

- Agent Discovery
- Preclinical Drug Development
- Clinical Trials Network
- Early detection and Screening
- Supportive care and Symptom Management
- Community Oncology Research
- Cancer Prevention Fellowship

Preventive Agent R&D Pipeline

Basic Science
Research (T_0)

Translation to
Humans (T_1)

Translation to
Patients (T_2)

Translation to
Practice (T_3)

Translation to
Community
(T_4)

CAP-IT
DDNP-CIP
CIP-Net


PREVENT

CP-CTNet

NCORP

Moonshot:
Immuno-
Oncology
Translation
Network (IOTN)

Investigator-Initiated Research



CAP-IT Program

Goal:

To discover molecularly or immunologically targeted agents designed to prevent or intercept the oncogenic process in higher-risk populations.

Network:

- 3 U54 Centers
- 1 U24 Center
- 2 Supplement awards
- 11 US locations and 1 international location

Funding Opportunity:

NOT-CA-24-07 – Next deadline Jun14

Notice of Special Interest (NOSI):
Administrative Supplement to Support
the NCI Cancer Prevention-Interception
Targeted Agent Discovery Program
(CAP-IT) Research



Shizuko Sei, M.D.,
Co-Chief



Vignesh Gunasekharan,
Ph.D.

CIP-Net Program

Goal:

To support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, preclinical development and testing of interventions, and foster a community of cancer immunoprevention researchers.

Funding Opportunity:

RFA-CA-23-029 – Next deadline Jul3

**Cancer Immunoprevention Network
(CIP-Net) Research Projects
(UG3/UH3 Clinical Trials Not Allowed)**



Altaf Mohammed, Ph.D.

DDNP-CIP Program

Goal:

To support the discovery and development of novel natural products that are safe, non-toxic, and efficacious for cancer interception and prevention.

Funding Opportunity:

RFA-CA-23-028 – Next deadline Jun13

Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)



Altaf Mohammed, Ph.D.

PREVENT Program

Goal:

To support preclinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials.

Success Metrics:

Since the inception of the Program in 2011, the Program has supported 132 projects and successfully helped move 9 interventions forward for clinical development.

Funding Opportunity:

Next deadline – July 8

Opportunity to partner with the NCI in accessing government resources to accelerate your research



Mark Miller, Ph.D.,
Deputy Chief
Director of Operations



Shizuko Sei, M.D.,
Co-Chief

Other Relevant Funding Opportunities

- NOT-CA-24-023 - Notice of Special Interest: National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Prevention
- PAR-21-322/23/24 - Basic Research in Cancer Health Disparities (R01/R21/R03 Clinical Trial Not Allowed)
- PAR-24-072 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)



Funding Opportunities | Division of
Cancer Preven...

prevention.cancer.gov

We are just an email away - Thank you!



**NATIONAL
CANCER
INSTITUTE**

cancer.gov

cancer.gov/espanol